Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, particularly Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury (mTBI). The Alpha Cognition news feed on Stock Titan aggregates company announcements, clinical updates, and capital markets disclosures so readers can follow how its Alzheimer’s and neuroscience programs progress over time.
News for ACOG frequently centers on the commercialization of ZUNVEYL, an FDA-approved new-generation acetylcholinesterase inhibitor for mild to moderate Alzheimer’s dementia in adults. Company releases describe launch momentum in the U.S. long-term care channel, including growth in pharmacy orders, expansion of the prescriber base, and increasing penetration into nursing homes. Updates also cover payer coverage developments, such as additional pharmacy benefit manager contracts, and the company’s efforts to deepen relationships with long-term care facilities.
Investors and healthcare observers will also find coverage of clinical and real-world evidence studies involving ZUNVEYL and ALPHA-1062, including planned and ongoing studies in Alzheimer’s disease patients in long-term care settings and research on cognitive impairment following traumatic brain injury. Alpha Cognition regularly reports on scientific presentations at meetings like the American Society of Consultant Pharmacists and the Neuroscience Education Institute, where it shares data on cholinesterase inhibitors, treatment persistence, and patient outcomes.
In addition, the ACOG news stream includes financing transactions, such as public offerings and at-the-market programs, licensing agreements for ZUNVEYL in Asia, and SEC-reportable events like changes in auditors or stock incentive plans. By reviewing this page, readers can track how Alpha Cognition’s commercial execution, clinical data, and corporate actions evolve, all in one consolidated news hub.
Alpha Cognition (NASDAQ: ACOG) reported Q3 2024 financial results and corporate updates. The company received FDA approval for ZUNVEYL, an Alzheimer's disease treatment, with commercial launch planned for Q1 2025. Key highlights include: $4.5M raised in bridge financing, successful manufacturing stability tests extending ZUNVEYL's shelf life to 24 months, and NASDAQ listing preparation. Financial results show Q3 2024 R&D expenses of $1.0M (down from $1.4M in Q3 2023), G&A expenses of $1.2M (up from $0.8M), and a net loss of $1.9M ($0.31 per share). Cash position stands at $3.7M as of September 30, 2024.
Alpha Cognition (ACOG) has announced the pricing of its upsized public offering of 8,695,653 common shares at $5.75 per share, raising approximately $50 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to 1,184,592 additional shares. The offering is expected to close on November 13, 2024. ACOG will begin trading on Nasdaq on November 12, 2024. Proceeds will fund the commercialization of ZUNVEYL for Alzheimer's Disease, pipeline development, CMC activities, and working capital.
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) reported financial results for Q2 and H1 2024, highlighting the FDA approval of ZUNVEYL for mild-to-moderate Alzheimer's disease. The company's R&D expenses decreased to $0.9 million in Q2 and $1.9 million in H1 2024, down from $1.3 million and $2.4 million in the same periods of 2023. G&A expenses increased to $1.2 million in Q2 and $4.4 million in H1 2024, up from $0.6 million and $1.3 million in 2023. The Q2 2024 net loss was $2.1 million ($0.01 per share), and H1 2024 net loss was $7.1 million ($0.05 per share). Cash and cash equivalents stood at $1.0 million as of June 30, 2024.